The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Ahu Demir - Ladenburg Thalmann - Analyst
: Thank you for the presentation, Sarma. I will just dive into a couple questions. Maybe on the high level, you could maybe give us some information
-- elaborate on the differentiating factors of Immunome compared to other companies such as Atreca, AIMM, AbCellera. What are the similarities
and differentiating key factors? There seem to be multiple differentiating factors and how do you see those potentially play out in advantage or
potential challenges for you?
Question: Ahu Demir - Ladenburg Thalmann - Analyst
: This is helpful, Sarma. So my follow-up question would be more focused on the ONC-01 asset. You are targeting IL-38, which indications are you
planning to assess, A, and is it going to be in monotherapy or combination setting? And how do you think about the market potential for this
program?
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
JULY 13, 2021 / 2:30PM, IMNM.OQ - Immunome Inc at Ladenburg Thalmann Virtual Healthcare Conference
Question: Ahu Demir - Ladenburg Thalmann - Analyst
: That's very helpful, Sarma. Just a couple minutes left, and I would like to focus on the coronavirus program as well. So you are utilizing [IDE] platform
for patients responding to COVID-19 viral outbreaks. And could you provide some [color] on the current status, recent developments, and also
potential next steps? And also the second part of the question is how many patients have you analyzed up until now?
Question: Ahu Demir - Ladenburg Thalmann - Analyst
: How many patient samples have you analyzed? Is there a number that you have disclosed publicly?
Question: Ahu Demir - Ladenburg Thalmann - Analyst
: Thank you so much for your participation and insights, Sarma. It was a pleasure and best of luck for the rest of the year. Thank you.
| 
